Evidence map›Paper›PMID 36549706›Full record

ArticleThe European respiratory journal2023

Interstitial lung disease progression after genomic usual interstitial pneumonia testing.

Sachin Chaudhary, S Sam Weigt, Manuel L Ribeiro Neto, Bryan S Benn, Janelle Vu Pugashetti, Rebecca Keith, Arista Chand, Scott Oh, Fayez Kheir, Vijaya Ramalingam and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.American journal of respiratory and critical care medicine · 2024
    Article
  7. Review
  8. Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2024
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Sachin ChaudharyDivision of Pulmonary and Critical Care Medicine, University of Arizona, Tucson, AZ, USA.
S Sam WeigtDivision of Pulmonary and Critical Care Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Manuel L Ribeiro NetoDepartment of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, USA.
Bryan S BennDivision of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Janelle Vu PugashettiDivision of Pulmonary, Critical Care and Sleep Medicine, University of California at Davis, Sacramento, CA, USA.ORCID 0000-0002-8889-2757
Rebecca KeithDivision of Pulmonary and Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.
Arista ChandDivision of Pulmonary and Critical Care Medicine, University of Arizona, Tucson, AZ, USA.
Scott OhDivision of Pulmonary and Critical Care Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Fayez KheirDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
Vijaya RamalingamDivision of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Joshua J SolomonDivision of Pulmonary and Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.
Richart HarperDivision of Pulmonary, Critical Care and Sleep Medicine, University of California at Davis, Sacramento, CA, USA.
Joseph A LaskyDivision of Pulmonary and Critical Care Medicine, Tulane University, New Orleans, LA, USA.
Justin M OldhamDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA oldhamj@med.umich.edu.
Medical College of Wisconsin · USNational Jewish Health · USUniversity of Arizona · USUniversity of California, Davis · USUniversity of California, Los Angeles · USCleveland Clinic · USMassachusetts General Hospital · USTulane University · USUniversity of Michigan · US

Funding

PULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M
Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary FibrosisK23HL138190 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OLDHAM, JUSTIN M · 2017 to 2021
$914k
NHLBI NIH HHS K23 HL138190NHLBI NIH HHS T32 HL007749
6 · The paper itself

Abstract

backgroundA genomic classifier for usual interstitial pneumonia (gUIP) has been shown to predict histological UIP with high specificity, increasing diagnostic confidence for idiopathic pulmonary fibrosis (IPF). Whether those with positive gUIP classification exhibit a progressive, IPF-like phenotype remains unknown.

methodsA pooled, retrospective analysis of patients who underwent clinically indicated diagnostic bronchoscopy with gUIP testing at seven academic medical centres across the USA was performed. We assessed the association between gUIP classification and 18-month progression-free survival (PFS) using Cox proportional hazards regression. PFS was defined as the time from gUIP testing to death from any cause, lung transplant, ≥10% relative decline in forced vital capacity (FVC) or censoring at the time of last available FVC measure. Longitudinal change in FVC was then compared between gUIP classification groups using a joint regression model.

resultsOf 238 consecutive patients who underwent gUIP testing, 192 had available follow-up data and were included in the analysis, including 104 with positive gUIP classification and 88 with negative classification. In multivariable analysis, positive gUIP classification was associated with reduced PFS (hazard ratio 1.58, 95% CI 0.86-2.92; p=0.14), but this did not reach statistical significance. Mean annual change in FVC was -101.8 mL (95% CI -142.7- -60.9 mL; p<0.001) for those with positive gUIP classification and -73.2 mL (95% CI -115.2- -31.1 mL; p<0.001) for those with negative classification (difference 28.7 mL, 95% CI -83.2-25.9 mL; p=0.30).

conclusionsgUIP classification was not associated with differential rates of PFS or longitudinal FVC decline in a multicentre interstitial lung disease cohort undergoing bronchoscopy as part of the diagnostic evaluation.

Indexed as

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialDisease ProgressionGenomicsHumansLungRetrospective StudiesVital Capacity

Identifiers

PMID36549706
PMCPMC10288658
OpenAlexW4312113381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.